Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …

The approval of the first immune checkpoint inhibitors provided a paradigm shift for the
treatment of malignancies across a broad range of indications. Whereas initially, single …

For many solid malignancies, lymph node (LN) involvement represents a harbinger of
distant metastatic disease and, therefore, an important prognostic factor. Beyond its utility as …

Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …

Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Intratumoral immune cells are crucial for tumor control and antitumor responses during
immunotherapy. Immune cell trafficking into tumors is mediated by binding of specific …

Background Interferon-γ (IFN-γ) plays a key role in activation of cellular immunity and
subsequently, stimulation of antitumor immune-response. Based on its cytostatic, pro …

Tebotelimab, a bispecific PD-1× LAG-3 DART molecule that blocks both PD-1 and LAG-3,
was investigated for clinical safety and activity in a phase 1 dose-escalation and cohort …

To define the cellular composition and architecture of cutaneous squamous cell carcinoma
(cSCC), we combined single-cell RNA sequencing with spatial transcriptomics and …

Recruitment of lymphocytes into tumors is critical for anti-tumor immunity and efficacious
immunotherapy. We show in murine models that tumor-associated high endothelial venules …